- DOET is a psychedelic drug of the phenethylamine and amphetamine chemical classes. It was first synthesized by Alexander Shulgin, and was described in his book PiHKAL (Phenethylamines i Have Known And Loved). DOET is an extremely rare compound and reports of its effects and toxicology in humans are sparse. DOET produces psychedelic effects that last up 14 - 20 hours.
EXTENSIONS AND COMMENTARY: The original code for this compound was DOE, which was completely logical based on DOM being the methyl member of this series (DO for the removal of the oxygen, desoxy, and M for putting a methyl in its place). And the putting of the ethyl thence should be DOE. This was fine until it was pointed out to me by a close colleague that DOE was a classic abbreviation for desoxyephedrine, a synonym for methamphetamine. The pressure to add the RTS of the RETS of the ethyl was heightened by looking ahead to other members of the series. DOA became DOAM, DOE became DOET, but DOM was already too firmly set in popular usage. And, anyway, DOME really looked strange.
A potent and long acting psychedelic stimulant and substituted amphetamine, similar in effects to other DOx compounds. First synthesised by Alexander Shulgin.
NOTE: These doses are tentative and may need further research.
Euphoria, empathy, insight, brightened colour, Closed/Open eye visuals, enhanced tactile sensation, mental/physical stimulation, decreased appetite, pupil dilation, restlessness, change in perception, ego softening, sweating/chills, muscle tension, confusion, insomnia.
A potent and long-acting psychedelic. Psychedelic effects that last up 14 - 20 hours
- DOET is a psychedelic drug
- Phenethylamine and amphetamine chemical classes
- It was first synthesized by Alexander Shulgin, and was described in his book PiHKAL (Phenethylamines i Have Known And Loved)
In PiHKAL, Shulgin lists the dosage of DOET as being 2 - 7 mg orally, with 6 - 7 mg being the dosage for full, desired effects.
Veterans Affairs will cover pricey experimental Alzheimer's drug - T he Veterans Health Administration (VHA) said it will widely cover an experimental $26,500-per-year Alzheimer's drug, even though Medicare will not. Leqembi will be made available to veterans ...
Tuesday March 14, 2023 - msn.com
|Hallucinogens | Link to this page